Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 152, Issue 6, Pages 733-742Publisher
WILEY
DOI: 10.1111/j.1365-2141.2010.08448.x
Keywords
Paediatric; post-transplant lymphoproliferative disease; CD20; EBV; survival
Categories
Funding
- Pediatric Cancer Research Foundation
- American Cancer Society
Ask authors/readers for more resources
P>The prognostic role of CD20 expression and Epstein-Barr virus (EBV) positivity in post-transplant lymphoproliferative disease (PTLD) after solid organ transplantation (SOT) in paediatric patients is poorly understood. We retrospectively examined the relationship of CD20 and EBV with the time interval from SOT to PTLD diagnosis, and PTLD-related event-free (EFS) and overall survival (OS) in 45 consecutive PTLD patients (< 25 years) following SOT. These 45 paediatric SOT patients (28 heart, 11 liver, six kidney) were diagnosed with PTLD 45 months (mean; SD 43; range 4-153; median 24 center dot 5) after SOT, with PTLD diagnosis at 118 months (mean) (SD 77; range 14-287) of age. Of 40 evaluable tumours (11 monomorphic, 19 polymorphic, five early lesions, five rare subtypes), 32 (80%) had detectable EBV and 28 (70%) were classified as CD20+. Patients whose PTLD expressed CD20 or EBV had shorter intervals between SOT and PTLD onset (28 vs. 64 or 77 months for CD20 and EBV respectively) (P < 0 center dot 02), even after adjusting for age at SOT. Patients with CD20+ tumours had higher 5-year PTLD-related EFS (83 center dot 7% vs. 28 center dot 6%, P < 0 center dot 001) and OS (95 center dot 8% vs. 56 center dot 3%, P = 0 center dot 01). EBV expression was unrelated to PTLD-related EFS or OS. CD20 expression is associated with timing of development of PTLD and predicts survival in PTLD diagnosed following paediatric SOT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available